Abstract
Objective
Ischemia-modified albumin (IMA) is a novel marker for the detection of ischemia. The value of this biomarker has been studied in patients with coronary artery disease (CAD). However, the relationship between the severity of coronary stenosis and serum IMA levels remains unknown. Therefore, we aimed to investigate the potential role of serum IMA levels in predicting the severity of coronary atherosclerosis.
Materials and methods
One hundred and forty-two individuals who underwent coronary angiography for coronary artery disease complaints were included in the study. Participants were divided into three groups based on their diagnosis as control (healthy subjects), group I (subjects with lower Gensini score), and group II (subjects with higher Gensini score). Global Registry of Acute Coronary Events (GRACE) risk score and Gensini scores were calculated after coronary angiogram in the patient groups. Then, venous blood samples were collected from each participant. Serum IMA levels and the levels of routine laboratory markers were measured.
Results
The serum lymphocyte, neutrophil, and high-density lipid (HDL) levels were statistically insignificant between the groups. The white blood cell (WBC) count and IMA levels were significantly higher in the patient groups (p < 0.05). The GRACE and Gensini scores were significantly different in the patient groups (p < 0.05). However, there was no significant correlation between the GRACE and Gensini scores and serum IMA levels.
Conclusion
Although IMA levels can be a significant predictor for ischemia according to previous reports, this biomarker seems to be insufficient for determining the severity of disease in patients with CAD.
Similar content being viewed by others
References
Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt–albumin binding and its potential as a marker for myocardial ischemia -- a preliminary report. J Emerg Med. 2000;19:311–5.
Caliskan A, Yavuz C, Karahan O, et al. Serum ischaemia-modified albumin level is an irrelevant predictive factor for ischaemic duration in mesenteric ischaemia. Perfusion. 2014;29:226–30.
Gaze DC. Ischemia modified albumin: a novel biomarker for the detection of cardiac ischemia. Drug Metab Pharmacokinet. 2009;24:333–41.
Talwalkar SS, Bon Homme M, Miller JJ, Elin RJ. Ischemia modified albumin, a marker of acute ischemic events: a pilot study. Ann Clin Lab Sci. 2008;38:132–7.
Shepard D, VanderZanden A, Moran A, Naghavi M, Murray C, Roth G. Ischemic heart disease worldwide, 1990 to 2013: estimates from the Global Burden of Disease Study 2013. Circ Cardiovasc Qual Outcomes. 2015;8:455–6.
Van Belle E, Dallongeville J, Vicaut E, Degrandsart A, Baulac C, Montalescot G; OPERA Investigators. Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study. Am Heart J. 2010;159:570–6.
Sinha MK, Roy D, Gaze DC, Collinson PO, Kaski JC. Role of “Ischemia modified albumin,” a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg Med J. 2004;21:29–34.
Demirtas AO, Karabag T, Demirtas D. Ischemic modified albumin predicts critical coronary artery disease in unstable angina pectoris and non-ST-elevation myocardial infarction. J Clin Med Res. 2018;10:570–5.
Yüksel M, Yıldız A, Oylumlu M, et al. The association between platelet/lymphocyte ratio and coronary artery disease severity. Anatol J Cardiol. 2015;15:640–7.
Alnasser SM, Huang W, Gore JM, et al. Late consequences of acute coronary syndromes: Global Registry of Acute Coronary Events (GRACE) follow-up. Am J Med. 2015;128:766–75.
Tsimikas S, Mallat Z, Talmud PJ, et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol. 2010;56:946–55.
Karahan O, Acet H, Ertaş F, et al. The relationship between fibrinogen to albumin ratio and severity of coronary artery disease in patients with STEMI. Am J Emerg Med. 2016;34:1037–42.
Gui MH, Li X, Lu ZQ, Gao X. Fasting plasma glucose correlates with angiographic coronary artery disease prevalence and severity in Chinese patients without known diabetes. Acta Diabetol. 2013;50:333–40.
Sinan Deveci O, Kabakci G, Okutucu S, et al. The association between serum uric acid level and coronary artery disease. Int J Clin Pract. 2010;64:900–7.
Kaya H, Ertaş F, İslamoğlu Y, et al. Association between neutrophil to lymphocyte ratio and severity of coronary artery disease. Clin Appl Thromb Hemost. 2014;20:50–4.
Roy D, Quiles J, Gaze DC, Collinson P, Kaski JC, Baxter GF. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart. 2006;92:113–4. https://doi.org/10.1136/hrt.2004.049643.
Chawla R, Goyal N, Calton R, Goyal S. Ischemia modified albumin: a novel marker for acute coronary syndrome. Indian J Clin Biochem. 2006;21:77–82. https://doi.org/10.1007/BF02913070.
Consuegra-Sanchez L, Bouzas-Mosquera A, Sinha MK, Collinson PO, Gaze DC, Kaski JC. Ischemia-modified albumin predicts short-term outcome and 1-year mortality in patients attending the emergency department for acute ischemic chest pain. Heart Vessel. 2008;23:174–80.
Hjortshøj S, Kristensen SR, Ravkilde J. Diagnostic value of ischemia-modified albumin in patients with suspected acute coronary syndrome. Am J Emerg Med. 2010;28:170–6.
Charpentier S, Ducassé JL, Cournot M, et al. Clinical assessment of ischemia-modified albumin and heart fatty acid-binding protein in the early diagnosis of non-ST-elevation acute coronary syndrome in the emergency department. Acad Emerg Med. 2010;17:27–35.
Oran I, Oran B. Ischemia-modified albumin as a marker of acute coronary syndrome: the case for revising the concept of “N-Terminal Modification” to “Fatty Acid Occupation” of albumin. Dis Markers. 2017;2017:5692583–8. https://doi.org/10.1155/2017/5692583.
Pasavand P, Salesi M, Mehrabi A, Amirazodi M, Koushki JM. Response of ischemia-modified albumin (IMA) plasma to the time of intensive exercise (morning and evening) in male patients with cardiovascular disease. Rep Health Care. 2019;5:35–43.
Parsanathan R, Jain SK. Novel invasive and noninvasive cardiac-specific biomarkers in obesity and cardiovascular diseases. Metab Syndr Relat Disord. 2020;18:10–30. https://doi.org/10.1089/met.2019.0073.
Mishra B, Pandey S, Niraula SR, et al. Utility of ischemia modified albumin as an early marker for diagnosis of acute coronary syndrome. J Nepal Health Res Counc. 2018;16:16–21.
Funding
Nil.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Human and animal rights
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Ethical approval
The study was approved by the Bioethics Committee of the Medical University of A (No. 7.25, 01/08/2019).
Informed consent
Informed consent was obtained from all involved participants included in the study.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Etli, M. Investigation of serum ischemia-modified albumin levels in coronary artery disease patients. Indian J Thorac Cardiovasc Surg 37, 147–152 (2021). https://doi.org/10.1007/s12055-020-01061-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12055-020-01061-5